Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $71.43 million. The enterprise value is $54.47 million.
| Market Cap | 71.43M |
| Enterprise Value | 54.47M |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 6.11 million shares outstanding. The number of shares has increased by 11.86% in one year.
| Current Share Class | 6.11M |
| Shares Outstanding | 6.11M |
| Shares Change (YoY) | +11.86% |
| Shares Change (QoQ) | +40.42% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 42.93% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.33 |
| Forward PS | 6.66 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.53
| Current Ratio | 0.53 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -62.39% |
| Return on Invested Capital (ROIC) | -192.94% |
| Return on Capital Employed (ROCE) | 260.39% |
| Weighted Average Cost of Capital (WACC) | 17.56% |
| Revenue Per Employee | $328,926 |
| Profits Per Employee | -$772,981 |
| Employee Count | 162 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -88,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.21% in the last 52 weeks. The beta is 2.00, so Gossamer Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.00 |
| 52-Week Price Change | -95.21% |
| 50-Day Moving Average | 13.06 |
| 200-Day Moving Average | 75.15 |
| Relative Strength Index (RSI) | 45.84 |
| Average Volume (20 Days) | 240,198 |
Short Selling Information
| Short Interest | 82.63M |
| Short Previous Month | 86.79M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $53.29 million and -$125.22 million in losses. Loss per share was -$51.97.
| Revenue | 53.29M |
| Gross Profit | 53.29M |
| Operating Income | -158.62M |
| Pretax Income | -125.31M |
| Net Income | -125.22M |
| EBITDA | -158.60M |
| EBIT | -158.62M |
| Loss Per Share | -$51.97 |
Balance Sheet
The company has $57.03 million in cash and $40.07 million in debt, with a net cash position of $16.96 million or $2.78 per share.
| Cash & Cash Equivalents | 57.03M |
| Total Debt | 40.07M |
| Net Cash | 16.96M |
| Net Cash Per Share | $2.78 |
| Equity (Book Value) | -94.03M |
| Book Value Per Share | -15.39 |
| Working Capital | -65.06M |
Cash Flow
| Operating Cash Flow | -162.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 21,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -162.63M |
| FCF Per Share | -$26.61 |
Margins
Gross margin is 100.00%, with operating and profit margins of -297.67% and -235.00%.
| Gross Margin | 100.00% |
| Operating Margin | -297.67% |
| Pretax Margin | -235.17% |
| Profit Margin | -235.00% |
| EBITDA Margin | -297.63% |
| EBIT Margin | -297.67% |
| FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.86% |
| Shareholder Yield | -11.86% |
| Earnings Yield | -176.21% |
| FCF Yield | -228.84% |
Analyst Forecast
The average price target for Gossamer Bio is $136.48, which is 1,067.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $136.48 |
| Price Target Difference | 1,067.49% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 18.14% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 11, 2026. It was a reverse split with a ratio of 1:80.
| Last Split Date | Sep 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:80 |
Scores
Gossamer Bio has an Altman Z-Score of -32.47 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.47 |
| Piotroski F-Score | 1 |